You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

35 Results
Drug
Other Name(s): Suprefact® , Suprefact Depot® , Suprefact Nasal Spray®
Nov 2024
Drug
Other Name(s): Casodex® (multiple brands available)
Apr 2024
Drug
Other Name(s): Abraxane®
Dec 2024
Drug
Nov 2024
Drug
Other Name(s): Bosulif®
Nov 2024
Drug
Other Name(s): Atriance®
Apr 2024
Regimen
Cancer Type:
Central Nervous System
Intent: Palliative
Jul 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Curative
Funding:
ODB - General Benefit
    procarbazine
ODB - General Benefit
    prednisone
Nov 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade, 
Lymphoma - T-cell
Intent: Palliative
Funding:
New Drug Funding Program
    Brentuximab Vedotin - Systemic Anaplastic Large Cell Lymphoma
Sep 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Palliative
Funding:
New Drug Funding Program
    Brentuximab Vedotin - Relapsed or Refractory Hodgkin Lymphoma
Sep 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Funding:
Exceptional Access Program
    bosutinib - For the treatment of patients with chronic, accelerated or blast phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML), according to specific criteria.
Nov 2024
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Hypersensitivity Reactions to Taxanes
Dec 2024

Pages